A groundbreaking Phase I clinical trial, approved by the FDA and China’s NMPA, is set to test a regenerative cell therapy aimed at reversing spinal cord injuries—a condition long considered irreversible. Developed by Chinese biotech firm XellSmart, this therapy could redefine treatment for millions affected by paralysis worldwide. Impact: Spinal cord injuries (SCI) have traditionally been managed through surgery and […]
World’s First Regenerative Cell Therapy Trial Offers New Hope for Spinal Cord Injury Recovery
Blossom App: Making Fixed-Income Investing Accessible for a New Generation
What began as a frustrating investment experience for Gaby Rosenberg became the spark for Blossom App—a fintech platform revolutionizing access to fixed-income investments for young Australians. Impact: Blossom App is lowering traditional barriers in the fixed-income market by offering low-minimum, high-access products tailored to younger investors. With over 26,000 users and A$112 million under management in just a few years, […]